<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10027326</article-id><article-id pub-id-type="pmc">2362412</article-id><article-id pub-id-type="pii">6690084</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690084</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Raderer</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hamilton</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kurtaran</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Valencak</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Haberl</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hoffmann</surname><given-names>O</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kornek</surname><given-names>G V</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vorbeck</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Hejna</surname><given-names>M H L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Virgolini</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Scheithauer</surname><given-names>W</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1">Department of Internal Medicine I, Division of Oncology, University of Vienna, Vienna, Austria</aff><aff id="aff2">Ludwig Boltzmann Institute of Clinical Oncology, KH Lainz, Vienna, Austria</aff><aff id="aff3">Department of Nuclear Medicine, University of Vienna, Vienna, Austria</aff><aff id="aff4">Department of Experimental Surgery, University of Vienna, Vienna, Austria</aff><aff id="aff5">Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria</aff><aff id="aff6">Department of Radiology, University of Vienna, Vienna, Austria</aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>Department of Internal Medicine I, Division of Oncology, University of Vienna, Waehringer Guertel 18&#x02013;20, A-1090 Vienna, Austria</corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>1999</year></pub-date><volume>79</volume><issue>3-4</issue><fpage>535</fpage><lpage>537</lpage><history><date date-type="received"><day>02</day><month>03</month><year>1998</year></date><date date-type="rev-recd"><day>27</day><month>05</month><year>1998</year></date><date date-type="accepted"><day>08</day><month>07</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Fourteen patients with metastatic pancreatic adenocarcinoma were treated with the long-acting somatostatin (SST) analogue lanreotide. No objective response was obtained, and the median survival was 4 months (range 1.8&#x02013;7 months). Pancreatic cancer could not be visualized by means of SST-receptor (R) scintigraphy in our patients. In vitro data also demonstrated absence of SSTR2 expression, suggesting pancreatic cancer not to be a potential target for treatment with SST analogues. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>lanreotide</kwd><kwd>pancreatic cancer</kwd><kwd>somatostatin receptors</kwd></kwd-group></article-meta></front></article>
